Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research Apoptosis 

    • Resisting apoptosis 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
      • Apoptosis
      • Resisting apoptosis
      • Apoptotic pathways
      • The Bcl-2 family
      • Reactivating apoptosis
      • Useful resources
      • References
      • Glossary
    • Research B cell
    • Research BRAF
    • Research HDIs
    • Research HER Pathways
    • Research MET
    • Research VEGF
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Molecular Causes of Cancer
    • Angiogenesis
      • Inducing angiogenesis
    • Apoptosis
      • Resisting cell death
    • Cell Metabolism
      • Reprogramming energy metabolism
    • Cellular Replication
      • Enabling replicative immortality
    • Evading the Immune System
      • Evading immune destruction
    • Genome Instability and Mutation
      • Genome instability and mutation
    • Growth Signaling
      • Evading growth suppressors
      • Sustaining proliferative signaling
    • Tissue Invasion and Metastasis
      • Activating invasion and metastasis
    • Tumor-promoting Inflammation
      • Tumor-promoting inflammation
  • Biological Pathways
    • Apoptotic Signaling
      • Apoptosis
  • Therapeutic Targets
    • BCL-2
      • Bcl-2
  • Future Directions
    • Antibody-Drug conjugates
      • Summary
      • A brief history of ADCs
      • Cancer effects
      • Current research in ADCs
      • Cytotoxic agent
      • Emerging therapeutic options
      • Emerging therapeutic options
      • HER2
      • HER ligands
      • HER pathways slide decks and videos
      • Glossary
      • Receptor activation
      • Dimerization
      • HER Signaling
      • Overview
      • HER1/EGFR evaluation
      • HER1/EGFR and prognosis
      • HER1/EGFR as a therapeutic target
      • Summary
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER2 dysregulation
      • HER2:HER3 dimer
      • HER2 and prognosis
      • HER2 detection methods
      • HER2 as a therapeutic target
      • HER2 in breast cancer
      • Summary
      • HER2 in ovarian cancer
      • HER3 dysregulation
      • HER3
      • HER3 evaluation
      • HER3 as a therapeutic target
      • HER3 in breast cancer
      • HER3 in ovarian cancer
      • HER4
      • How are ADCs designed to work?
      • Glossary
      • Monoclonal antibody
      • Multimedia Resources
      • Receptor-Mediated Endocytosis
      • Research ADCs
      • Research MET
      • Stable linker
      • HER receptors
      • Summary
      • Targeting cancers with ADCs
      • Therapeutic potential of HER pathways
      • What are ADCs?
      • What is Met?
    • Apoptosis
      • Emerging therapeutic options
    • Bispecific Monoclonal Antibodies
      • Emerging therapeutic options
      • Emerging therapeutic options
      • Emerging therapeutic options
    • Glycoengineered Antibodies
      • Emerging therapeutic options
      • Emerging therapeutic options
      • HER Signaling
      • Emerging therapeutic options
    • Non-Antibody Biologics
      • Apoptosis
      • Extrinsic pathway
      • What are the strategies for inhibiting the VEGF pathway?
    • Targeted Small Molecules
      • Summary
      • Apoptosis
      • Apoptotic pathways
      • The Bcl-2 family
      • Cancer effects
      • Apoptosis
      • Emerging therapeutic options
      • Emerging therapeutic options
      • HER2
      • Gastric Cancer
      • HER ligands
      • HER pathways slide decks and videos
      • Glossary
      • Receptor activation
      • Dimerization
      • Overview
      • HER1/EGFR evaluation
      • HER1/EGFR and prognosis
      • HER1/EGFR as a therapeutic target
      • Summary
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER2 dysregulation
      • HER2:HER3 dimer
      • HER2 and prognosis
      • HER2 detection methods
      • HER2 as a therapeutic target
      • HER2 in breast cancer
      • Summary
      • HER2 in ovarian cancer
      • HER3 dysregulation
      • HER3
      • HER3 evaluation
      • HER3 as a therapeutic target
      • HER3 in breast cancer
      • HER3 in ovarian cancer
      • HER4
      • Glossary
      • MAPK Signaling
      • MEK Inhibitor (GDC-0973)
      • Emerging therapeutic options
      • PI3K Inhibitor (GDC-0941)
      • Reactivating apoptosis
      • Research MET
      • HER receptors
      • Summary
      • PI3K/Akt/mTOR Signaling
      • Therapeutic potential of HER pathways
      • Slide decks and videos
      • What are the strategies for inhibiting the VEGF pathway?
      • What is Met?
    • Traditional Monoclonal Antibodies
      • Summary
      • Anti-EGFL7
      • B-cell Surface Proteins
      • Cancer effects
      • Glossary
      • Direct cell death
      • Emerging therapeutic options
      • Emerging therapeutic options
      • HER2
      • Gastric Cancer
      • HER ligands
      • HER pathways slide decks and videos
      • Glossary
      • Receptor activation
      • Dimerization
      • HER Signaling
      • Overview
      • HER1/EGFR evaluation
      • HER1/EGFR and prognosis
      • HER1/EGFR as a therapeutic target
      • Summary
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER2 dysregulation
      • HER2:HER3 dimer
      • HER2 and prognosis
      • HER2 detection methods
      • HER2 as a therapeutic target
      • HER2 in breast cancer
      • Summary
      • HER2 in ovarian cancer
      • HER3 dysregulation
      • HER3
      • HER3 evaluation
      • HER3 as a therapeutic target
      • HER3 in breast cancer
      • HER3 in ovarian cancer
      • HER4
      • Emerging therapeutic options
      • Research MET
      • HER receptors
      • Summary
      • Angiogenic Signaling
      • Inhibition of HER2 dimerization
      • Therapeutic potential of HER pathways
      • Slide decks and videos
      • What are the strategies for inhibiting the VEGF pathway?
      • What is Met?

Apoptosis slide deck

Video

View the apoptosis mode of action slide deck

View slide deck
Share

Resisting apoptosis: a hallmark of cancer

Cancer cells that avoid apoptosis continue to proliferate uncontrollably, which results in an increased tumor mass. Resisting apoptosis is a key process in cancer development and progression (Figure 2.1).1,2

Figure 2.1 - The Hallmarks of Cancer
Enlarge this image

Adapted from Cell, 144, Hanahan D, Weinberg RA, The hallmarks of cancer: the next generation, 666-674, copyright © 2011, with permission from Elsevier.2

Cells resist apoptosis if they have an overexpression of anti-apoptotic proteins, such as Bcl-2, Bcl-XL, or IAP proteins. When these anti-apoptotic proteins are overexpressed, the cell’s ability to resist apoptosis is increased, and the cells will continue to proliferate, regardless of pro-apoptotic cues.2,10

Virtually all cancer cells are prone to resisting apoptosis.11 Understanding the mechanisms of resistance to apoptosis may lead to the development of therapies that can reprogram cell death.2

 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: Apoptotic pathways »

© 2011 Genentech USA, Inc. All rights reserved